Corbus Pharmaceuticals, Inc.
100 River Ridge Drive
Norwood
Massachusetts
02062
United States
Tel: 617-963-0100
Fax: 617-663-6085
Website: http://www.corbuspharma.com/
124 articles about Corbus Pharmaceuticals, Inc.
-
This is the latest rundown of people coming and going from executive positions at biopharma companies that BioSpace covers. This regular column highlights the hired, fired, retired, promoted or resigning, as well as those personally named in lawsuits.
-
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
3/12/2024
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the fourth quarter of 2023 and year-ended 2023.
-
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
3/6/2024
Corbus Pharmaceuticals Holdings, Inc. today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion at BMO Capital Markets Inaugural BMO Obesity Summit to be held on March 20, 2024 in New York City, NY.
-
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
2/28/2024
Corbus Pharmaceuticals Holdings, Inc., a precision oncology company with a diversified portfolio, announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company’s Chief Medical Officer.
-
Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
2/2/2024
Corbus Pharmaceuticals Holdings, Inc. announced the closing of its public offering of 4,973,750 shares of its common stock, including 648,750 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares.
-
Corbus Pharmaceuticals Announces Pricing of Public Offering
1/31/2024
Corbus Pharmaceuticals Holdings, Inc. today announced the pricing of an underwritten public offering of 4,325,000 shares of its common stock at a public offering price of $19.00 per share.
-
Corbus Pharmaceuticals Announces Proposed Public Offering - Jan 30, 2024
1/30/2024
Corbus Pharmaceuticals Holdings, Inc., a precision oncology company with a diversified portfolio, announced that it plans to offer and sell shares of its common stock or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock in an underwritten registered public offering.
-
Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/7/2023
Corbus Pharmaceuticals Holdings, Inc. today provided a corporate update and reported financial results for the third quarter of 2023.
-
Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting
11/2/2023
Corbus Pharmaceuticals Holdings, Inc. announced that results from two pre-clinical studies on its CRB-601 anti-aVb8 integrin monoclonal antibody were presented as posters at the 38th Annual Meeting of the Society for Immunotherapy of Cancer, being held in San Diego, CA November 1-5, 2023.
-
Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023
10/3/2023
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that it will host a Virtual ‘Meet the Expert’ event on the development of a next generation Nectin-4 antibody drug conjugate, focusing on opportunities and challenges for CRB-701, on Tuesday, October 10, 2023 at 10:30am ET.
-
Corbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9/19/2023
Corbus Pharmaceuticals Holdings, Inc. today announced the pre-clinical data on its CRB-701 Nectin-4 anti-drug-conjugate (ADC) will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
-
Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8/8/2023
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today provided a corporate update and reported financial results for the second quarter of 2023.
-
Corbus Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
7/31/2023
Corbus Pharmaceuticals Holdings, Inc. today announced that Yuval Cohen , Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the BTIG Virtual Biotechnology Conference, to be held August 7-8, 2023.
-
Corbus Pharmaceuticals Set to Join Russell Microcap® Index
6/26/2023
Corbus Pharmaceuticals Holdings, Inc. today announced that the Company is set to join the Russell Microcap® Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens today.
-
Corbus Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference
5/31/2023
Corbus Pharmaceuticals Holdings, Inc. today announced that Yuval Cohen , Ph.D., Chief Executive Officer of Corbus, will participate in a Fireside Chat at the 2023 Jefferies Healthcare Conference, to be held in New York, NY June 7-9, 2023.
-
Corbus Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
5/9/2023
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today provided a corporate update and reported financial results for the first quarter of 2023.
-
Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on CRB-601 avβ8 Blocking Antibody at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy Meeting
5/1/2023
Corbus Pharmaceuticals Holdings, Inc. today announced that an abstract highlighting pre-clinical data for CRB-601, its avβ8 blocking antibody, has been accepted for oral presentation in the main program of the New York Academy of Sciences' 2023 Frontiers in Cancer Immunotherapy meeting, taking place in New York, NY May 2-4, 2023.
-
Corbus Pharmaceuticals Hosting Virtual 'Meet the Expert' Series: Blocking TGFβ with CRB-601--a New Play for an Old Target
4/18/2023
Corbus Pharmaceuticals Holdings, Inc., a precision oncology company, announced that the Company will host the first in the series of virtual 'Meet the Expert' events titled Blocking TGFβ with CRB-601—a New Play for an Old Target, on April 25th at 11:00 AM ET.
-
Corbus Pharmaceuticals Presents Latest Pre-Clinical Data on CRB-601 at the 2023 American Association for Cancer Research Annual Meeting
4/17/2023
Corbus Pharmaceuticals Holdings, Inc. today announced details of new pre-clinical data on CRB-601, its avβ8 blocking antibody, presented as a poster at the 2023 American Association for Cancer Research (AACR) annual meeting, held April 14-19, 2023 in Orlando, FL.
-
Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update
3/7/2023
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today provided a corporate update and reported financial results for the fourth quarter and year-end of 2022.